{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:35:34Z","timestamp":1792751734843,"version":"4.5.0"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:00:00Z","timestamp":1535587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ital J Pediatr"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13052-018-0529-2","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T10:17:40Z","timestamp":1535019460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks"],"prefix":"10.1186","volume":"44","author":[{"given":"Alessandra","family":"Marchesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Tarissi de Jacobis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rimini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Corsello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Buonuomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Cardinale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Cortis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"De Zorzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzia","family":"Duse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Del Principe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Dellepiane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"D\u2019Isanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"El Hachem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Falcini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugo","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Maggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savina","family":"Mannarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Marseglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Marucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Massaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Pescosolido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Pietraforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Cristina","family":"Pietrogrande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Salice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelio","family":"Secinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Straface","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Villani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,30]]},"reference":[{"key":"529_CR1","doi-asserted-by":"publisher","first-page":"e927","DOI":"10.1161\/CIR.0000000000000484","volume":"135","author":"BW McCrindle","year":"2017","unstructured":"McCrindle BW, Rowley AH, Newburger JW, Burns JC, Bolger AF, Gewitz M, et al. Diagnosis, treatment, and long-term Management of Kawasaki Disease, a scientific statement for health professionals from the American heart. Circulation. 2017;135:e927\u201399.","journal-title":"Circulation."},{"key":"529_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65:1\u201311.","journal-title":"Arthritis Rheum."},{"key":"529_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2013.04.004","volume":"67","author":"S Esposito","year":"2013","unstructured":"Esposito S, Rigante D, Principi N. The role of infection in Kawasaki syndrome. J Infect. 2013;67:1\u201310.","journal-title":"J Infect"},{"key":"529_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s12026-015-8679-4","volume":"64","author":"D Rigante","year":"2016","unstructured":"Rigante D, Tarantino G, Valentini P. Non-infectious makers of Kawasaki syndrome: tangible or elusive triggers? Immunol Res. 2016;64:51\u20134.","journal-title":"Immunol Res."},{"key":"529_CR5","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1161\/01.CIR.87.5.1776","volume":"87","author":"AS Dajani","year":"1993","unstructured":"Dajani AS, Taubert KA, Gerber MA, Shulman ST, Ferrieri P, Freed M, et al. Diagnosis and therapy of Kawasaki disease in children. Circulation. 1993;87:1776\u201380.","journal-title":"Circulation."},{"key":"529_CR6","first-page":"1708","volume":"114","author":"JW Newburger","year":"2004","unstructured":"Newburger JW, Takahashi M, Gerber MA, Gewitz MH, Tani LY, Burns JC, et al. Diagnosis, treatment, and long-term management in Kawasaki disease: a statement for health professionals from the committee on rheumatic fever, endocarditis and Kawasaki disease, council on cardiovascular disease in the young. American Heart Association. Pediatrics. 2004;114:1708\u201333.","journal-title":"American Heart Association. Pediatrics."},{"key":"529_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1546-0096-9-17","volume":"9","author":"F Falcini","year":"2011","unstructured":"Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. Pediatr Rheumatol. 2011;9:17.","journal-title":"Pediatr Rheumatol."},{"key":"529_CR8","first-page":"301","volume":"11","author":"G De Rosa","year":"2007","unstructured":"De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. Eur Rev Med Pharmacol Sci. 2007;11:301\u20138.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"529_CR9","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrrheum.2015.54","volume":"11","author":"ST Shulman","year":"2015","unstructured":"Shulman ST, Rowley AH. Kawasaki disease: insights into pathogenesis and approaches to treatment. Nat Rev Rheumatol. 2015;11:475\u201382.","journal-title":"Nat Rev Rheumatol."},{"key":"529_CR10","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00296-009-1337-1","volume":"30","author":"D Rigante","year":"2010","unstructured":"Rigante D, Valentini P, Rizzo D, Leo A, De Rosa G, Onesimo R, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. Rheumatol Int. 2010;30:841\u20136.","journal-title":"Rheumatol Int"},{"key":"529_CR11","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00431-013-2101-9","volume":"172","author":"HM Yang","year":"2013","unstructured":"Yang HM, Du ZD FPP. Clinical features of recurrent Kawasaki disease and its risk factors. Eur J Pediatr. 2013;172:1641\u20137.","journal-title":"Eur J Pediatr"},{"key":"529_CR12","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1097\/00006454-199812000-00009","volume":"17","author":"JC Burns","year":"1998","unstructured":"Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP. Intravenous gamma-globulin treatment and retreatment of Kawasaki disease. US\/Canadian Kawasaki Syndrome Study Group. Pediatr Infect Dis J. 1998;17:1144\u20138.","journal-title":"Pediatr Infect Dis J."},{"key":"529_CR13","doi-asserted-by":"publisher","DOI":"10.1542\/peds.105.6.e78","volume":"105","author":"CA Wallace","year":"2000","unstructured":"Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gamma-globulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:e78.","journal-title":"Pediatrics."},{"key":"529_CR14","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1097\/INF.0b013e3181f386db","volume":"30","author":"M Seki","year":"2011","unstructured":"Seki M, Kobayashi T, Kobayashi T, Morikawa A, Otani T, Takeuchi K, et al. External validation of a risk score to predict intravenous immunoglobulin resistance in patients with Kawasaki disease. Pediatr Infect Dis J. 2011;30:145\u20137.","journal-title":"Pediatr Infect Dis J."},{"issue":"3","key":"529_CR15","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3390\/ijms17030278","volume":"17","author":"D Rigante","year":"2016","unstructured":"Rigante D, Andreozzi L, Fastiggi M, Bracci B, Natale MF, Esposito S. Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. Int J Mol Sci. 2016;17(3):278.","journal-title":"Int J Mol Sci."},{"key":"529_CR16","doi-asserted-by":"crossref","unstructured":"McCrindle BW, Li JS, Minich LL, Colan SD, Atz AM, Takahashi M, et al. Pediatric Heart Network Investigators. Coronary artery involvement in children with Kawasaki disease: risk factors from analysis of serial normalized measurements. Circulation. 2007;116:174-9.","DOI":"10.1161\/CIRCULATIONAHA.107.690875"},{"key":"529_CR17","doi-asserted-by":"crossref","unstructured":"Joint Working Groups: the Japanese Circulation Society, The Japanese Society of Kawasaki Disease, The Japanese Association for Thoracic Surgery, The Japan Pediatric Society, The Japanese Society of Pediatric Cardiology and Cardiac Surgery, The Japanese College of Cardiology. Guidelines for Diagnosis and Management of Cardiovascular Sequelae in Kawasaki disease (JCS 2013). Circ J. 2014;78:2521\u201362.","DOI":"10.1253\/circj.CJ-66-0096"},{"key":"529_CR18","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00467-009-1336-1","volume":"25","author":"MJ Dillon","year":"2010","unstructured":"Dillon MJ, Eleftheriou D, Brogan PA. Medium-size-vessel vasculitis. Pediatr Nephrol. 2010;25:1641\u201352.","journal-title":"Pediatr Nephrol."},{"key":"529_CR19","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1136\/adc.86.4.286","volume":"86","author":"PA Brogan","year":"2002","unstructured":"Brogan PA, Bose A, Burgner D, Shingadia D, Tulloh R, Michie C, et al. Kawasaki disease: an evidence based approach to diagnosis, treatment, and proposals for future research. Arch Dis Child. 2002;86:286\u201390.","journal-title":"Arch Dis Child."},{"key":"529_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1111\/j.1440-1754.2004.00456.x","volume":"40","author":"N Wilson","year":"2004","unstructured":"Wilson N, Heaton P, Calder L, Nicholson R, Stables S, Gavin R. Kawasaki disease with severe cardiac sequelae: lessons from recent New Zealand experience. J Paediatr Child Health. 2004;40:524\u20139.","journal-title":"J Paediatr Child Health"},{"key":"529_CR21","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1111\/j.1442-200x.2004.01943.x","volume":"46","author":"A Suzuki","year":"2004","unstructured":"Suzuki A, Miyagawa-Tomita S, Komatsu K, Nakazawa M, Fukaya T, Baba K, et al. Immunohistochemical study of apparently intact coronary artery in a child after Kawasaki disease. Pediatr Int. 2004;46:590\u20136.","journal-title":"Pediatr Int."},{"key":"529_CR22","first-page":"53","volume":"10","author":"A Stabile","year":"2006","unstructured":"Stabile A, Bertoni B, Ansuini V, La Torraca I, Sall\u00ec A, Rigante D. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. Eur Rev Med Pharmacol Sci. 2006;10:53\u20139.","journal-title":"Eur Rev Med Pharmacol Sci."},{"key":"529_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.semarthrit.2014.07.007","volume":"44","author":"W Wang","year":"2015","unstructured":"Wang W, Gong F, Zhu W, Fu S, Zhang Q. Macrophage activation syndrome in Kawasaki disease: more common than we thought? Semin Arthritis Rheum. 2015;44:405\u201310.","journal-title":"Semin Arthritis Rheum."},{"key":"529_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","volume":"149","author":"A Ravelli","year":"2005","unstructured":"Ravelli A, Magni-Manzoni S, Pistorio A, Besana C, Foti T, Ruperto N, et al. Preliminary diagnostic guidelines for macropphage activation syndrome complicating systemic juvenile arthritis. J Pediatr. 2005;149:598\u2013604.","journal-title":"J Pediatr."},{"key":"529_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.5045\/br.2013.48.4.254","volume":"48","author":"HR Kang","year":"2013","unstructured":"Kang HR, Kwon YH, Yoo ES, Ryu KH, Kim JY, Kim HS, et al. Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki. Blood Res. 2013;48:254\u20137.","journal-title":"Blood Res"},{"key":"529_CR26","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.1542\/peds.2008-1871","volume":"123","author":"JT Kanegaye","year":"2009","unstructured":"Kanegaye JT, Wilder MS, Molkara D, Frazer JR, Pancheri J, Tremoulet AH, et al. Recognition of a Kawasaki disease shock syndrome. Pediatrics. 2009;123:e783\u20139.","journal-title":"Pediatrics."},{"key":"529_CR27","doi-asserted-by":"crossref","unstructured":"Yang HM, Du ZD, Fu PP. Clinical features of recurrent Kawasaki disease and its risk factors. Eur J Pediatr. 2013;172:1641\u20137.","DOI":"10.1007\/s00431-013-2101-9"},{"issue":"8","key":"529_CR28","first-page":"RA179","volume":"15","author":"D Rigante","year":"2009","unstructured":"Rigante D. Autoinflammatory syndromes behind the scenes of recurrent fevers in children. Med Sci Monit. 2009;15(8):RA179\u201387.","journal-title":"Med Sci Monit."},{"key":"529_CR29","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1080\/1744666X.2017.1280396","volume":"13","author":"D Rigante","year":"2017","unstructured":"Rigante D. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. Expert Rev Clin Immunol. 2017;13:571\u201397.","journal-title":"Expert Rev Clin Immunol."},{"key":"529_CR30","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00431-008-0727-9","volume":"168","author":"K Okada","year":"2009","unstructured":"Okada K, Hara J, Maki I, Miki K, Matsuzaki K, Matsuoka T, et al. Pulse methylprednisolone with gammaglobulin as an initial treatment for acute Kawasaki disease. Eur J Pediatr. 2009;168:181\u20135.","journal-title":"Eur J Pediatr."},{"key":"529_CR31","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1542\/peds.2011-0148","volume":"129","author":"S Ogata","year":"2012","unstructured":"Ogata S, Ogihara Y, Honda T, Kon S, Akiyama K, Ishii M. Corticosteroid pulse combination therapy for refractory Kawasaki disease: a randomized trial. Pediatrics. 2012;129:e17\u201323.","journal-title":"Pediatrics."},{"key":"529_CR32","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/S0140-6736(11)61930-2","volume":"379","author":"T Kobayashi","year":"2012","unstructured":"Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease: a prospective, randomised, open, blinded-endpoint trial. Lancet. 2012;379:1613\u201320.","journal-title":"Lancet."},{"key":"529_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1056\/NEJMoa061235","volume":"356","author":"JW Newburger","year":"2007","unstructured":"Newburger JW, Sleeper LA, McCrindle BW, Minich LL, Gersony W, Vetter VL, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med. 2007;356:663\u201375.","journal-title":"N Engl J Med."},{"key":"529_CR34","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1093\/pch\/16.8.479","volume":"16","author":"M Miura","year":"2011","unstructured":"Miura M, Tamame T, Naganuma T, Chinen S, Matsuoka M, Ohki H. Steroid pulse therapy for Kawasaki disease unresponsive to additional immunoglobulin therapy. Paediatr Child Health. 2011;16:479\u201384.","journal-title":"Paediatr Child Health."},{"key":"529_CR35","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1136\/adc.2004.062299","volume":"90","author":"M Miura","year":"2005","unstructured":"Miura M, Ohki H, Yoshiba S, Ueda H, Sugaya A, Satoh M, et al. Adverse effects of methylprednisolone pulse therapy in refractory Kawasaki disease. Arch Dis Child. 2005;90:1096\u20137.","journal-title":"Arch Dis Child."},{"key":"529_CR36","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/adc.2007.126144","volume":"93","author":"T Furukawa","year":"2008","unstructured":"Furukawa T, Kishiro M, Akimoto K, Nagata S, Shimizu T, Yamashiro Y. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Arch Dis Child. 2008;93:142\u20136.","journal-title":"Arch Dis Child."},{"key":"529_CR37","first-page":"e91","volume":"20","author":"Y Etoom","year":"2013","unstructured":"Etoom Y, Banihani R, Finkelstein Y. Critical review of efficacy of immunoglobulin plus prednisone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial. J Popul Ther Clin Pharmacol. 2013;20:e91\u20134.","journal-title":"J Popul Ther Clin Pharmacol."},{"key":"529_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2010.08.070","volume":"154","author":"K Millar","year":"2012","unstructured":"Millar K, Manlhiot C, Yeung RS, Somji Z, McCrindle BW. Corticosteroid administration for patients with coronary artery aneurysms after Kawasaki disease may be associated with impaired regression. Int J Cardiol. 2012;154:9\u201313.","journal-title":"Int J Cardiol."},{"key":"529_CR39","doi-asserted-by":"publisher","first-page":"6294","DOI":"10.4049\/jimmunol.176.10.6294","volume":"176","author":"JS Hii-Yuen","year":"2006","unstructured":"Hii-Yuen JS, Duong TT, Yeung RSM. TNF-\u03b1 is necessary for induction of coronary artery inflammation and aneurysm formation in an animal model of Kawasaki disease. J Immunol. 2006;176:6294\u2013301.","journal-title":"J Immunol."},{"key":"529_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jpeds.2005.07.039","volume":"149","author":"T Saji","year":"2006","unstructured":"Saji T, Kemmotsu Y. Infliximab for Kawasaki syndrome. J Pediatr. 2006;149:426.","journal-title":"J Pediatr."},{"key":"529_CR41","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1203\/PDR.0b013e31819ed68d","volume":"65","author":"K Hirono","year":"2009","unstructured":"Hirono K, Kemmotsu Y, Wittkowski H, Foell D, Saito K, Ibuki K, et al. Infliximab reduces the cytokine-mediated inflammation but does not suppress cellular infiltration of the vessel wall in refractory Kawasaki disease. Pediatr Res. 2009;65:696\u2013701.","journal-title":"Pediatr Res."},{"key":"529_CR42","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13643-016-0236-2","volume":"5","author":"O Nomura","year":"2016","unstructured":"Nomura O, Fukuda S, Ota E, Ono H, Ishiguro A, Kobayashi T. Monoclonal antibody therapy for Kawasaki disease: a protocol for systematic reviews and meta-analysis. Syst Rev. 2016;5:60.","journal-title":"Syst Rev."},{"key":"529_CR43","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jpeds.2004.12.022","volume":"146","author":"JC Burns","year":"2005","unstructured":"Burns JC, Mason WH, Hauger SB, Janai H, Bastian JF, Wohrley JD, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr. 2005;146:662\u20137.","journal-title":"J Pediatr."},{"key":"529_CR44","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1080\/03009740600588228","volume":"35","author":"EV Stenbog","year":"2006","unstructured":"Stenbog EV, Windelborg B, H\u00f8rlyck A, Herlin T. The effect of TNF-alpha blockade in complicated, refractory Kawasaki disease. Scand J Rheumatol. 2006;35:318\u201321.","journal-title":"Scand J Rheumatol."},{"key":"529_CR45","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/0009922806294842","volume":"46","author":"MJ O\u2019Connor","year":"2007","unstructured":"O\u2019Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr. 2007;46:345\u20138.","journal-title":"Clin Pediatr."},{"key":"529_CR46","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1253\/circj.72.850","volume":"72","author":"T Oishi","year":"2008","unstructured":"Oishi T, Fujieda M, Shiraishi T, Ono M, Inoue K, Takahashi A, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J. 2008;72:850\u20132.","journal-title":"Circ J."},{"key":"529_CR47","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s12098-008-0084-8","volume":"75","author":"M Girish","year":"2008","unstructured":"Girish M, Subramaniam G. Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr. 2008;75:521\u20132.","journal-title":"Indian J Pediatr."},{"key":"529_CR48","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153:833\u20138.","journal-title":"J Pediatr."},{"key":"529_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-7-3","volume":"7","author":"RJ Brogan","year":"2009","unstructured":"Brogan RJ, Eleftheriou D, Gnanapragasam J, Klein NJ, Brogan PA. Infliximab for the treatment of intravenous immunoglobulin resistant Kawasaki disease complicated by coronary artery aneurysms: a case report. Pediatr Rheumatol. 2009;7:1\u20135.","journal-title":"Pediatr Rheumatol."},{"issue":"3 Suppl 97","key":"529_CR50","first-page":"S134","volume":"34","author":"S Singh","year":"2016","unstructured":"Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India. Clin Exp Rheumatol. 2016;34(3 Suppl 97):S134\u20138.","journal-title":"Clin Exp Rheumatol."},{"key":"529_CR51","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3899\/jrheum.110877","volume":"39","author":"M Mori","year":"2012","unstructured":"Mori M, Imagawa T, Hara R, Kikuchi M, Hara T, Nozawa T, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label case series. J Rheumatol. 2012;39:864\u20137.","journal-title":"J Rheumatol."},{"key":"529_CR52","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1097\/INF.0b013e3181e05564","volume":"29","author":"DA Shirley","year":"2010","unstructured":"Shirley DA, Stephens I. Primary treatment of incomplete Kawasaki disease with infliximab and methylpredonisolone in a patient with a contraindication to intravenous immune globulin. Pediatr Infect Dis J. 2010;29:978\u20139.","journal-title":"Pediatr Infect Dis J."},{"key":"529_CR53","doi-asserted-by":"publisher","first-page":"194864","DOI":"10.1155\/2015\/194864","volume":"2015","author":"G Lopalco","year":"2015","unstructured":"Lopalco G, Cantarini L, Vitale A, Iannone F, Anelli MG, Andreozzi L, et al. Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: premises, perils, and perspectives. Mediators Inflamm. 2015;2015:194864.","journal-title":"Mediators Inflamm."},{"key":"529_CR54","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1161\/CIRCULATIONAHA.111.072769","volume":"125","author":"YH Lee","year":"2012","unstructured":"Lee YH, Schulte DJ, Shimada K, Chen S, Crother TR, Chiba N, et al. IL-1\u03b2 is crucial for induction of coronary artery inflammation in a mouse model of Kawasaki disease. Circulation. 2012;125:1542\u201350.","journal-title":"Circulation"},{"key":"529_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/14397595.2014.902747","volume":"25","author":"S Yokota","year":"2015","unstructured":"Yokota S, Kikuchi M, Nozawa T, Kanetaka T, Sato T, Yamazaki K, et al. Pathogenesis of systemic inflammatory diseases in childhood: Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome. Mod Rheumatol. 2015;25:1\u201310.","journal-title":"Mod Rheumatol"},{"key":"529_CR56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.imlet.2017.11.013","volume":"193","author":"D Rigante","year":"2018","unstructured":"Rigante D. New mosaic tiles in childhood hereditary autoinflammatory disorders. Immunol Lett. 2018;193:67\u201376.","journal-title":"Immunol Lett."},{"key":"529_CR57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/ng.2007.59","volume":"40","author":"Y Onouchi","year":"2008","unstructured":"Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet. 2008;40:35\u201342.","journal-title":"Nat Genet."},{"key":"529_CR58","first-page":"99","volume":"54","author":"Japan Apheresis Society Scientific Committee","year":"2005","unstructured":"Japan Apheresis Society Scientific Committee. The present state of apheresis (results of the 2002 survey). Japan Apher Soc. 2005;54:99\u2013103.","journal-title":"Japan Apher Soc."},{"key":"529_CR59","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","volume":"36","author":"JS Alpert","year":"2000","unstructured":"Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined: A consensus document of The Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000;36:959\u201369.","journal-title":"J Am Coll Cardiol."},{"key":"529_CR60","doi-asserted-by":"publisher","first-page":"e234","DOI":"10.1542\/peds.2009-0606","volume":"125","author":"ES Yellen","year":"2010","unstructured":"Yellen ES, Gauvreau K, Takahashi M, Burns JC, Shulman S, Baker AL, et al. Performance of 2004 American Heart Association recommendations for treatment of Kawasaki disease. Pediatrics. 2010;125:e234\u201341.","journal-title":"Pediatrics."},{"key":"529_CR61","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/CRD.0b013e31802ea93f","volume":"15","author":"GM Satou","year":"2007","unstructured":"Satou GM, Giamelli J, Gewitz MH. Kawasaki disease: diagnosis, management, and long-term implications. Cardiol Rev. 2007;15:163\u20139.","journal-title":"Cardiol Rev."},{"key":"529_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/MOP.0b013e32835c1122","volume":"25","author":"SR Dominguez","year":"2013","unstructured":"Dominguez SR, Anderson MS. Advances in the treatment of Kawasaki disease. Curr Opin Pediatr. 2013;25:103\u20139.","journal-title":"Curr Opin Pediatr."},{"key":"529_CR63","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.1161\/01.cir.0000436140.77832.7a","volume":"128","author":"TM Giglia","year":"2013","unstructured":"Giglia TM, Massicotte MP, Tweddell JS, Barst RJ, Bauman M, Erickson CC, et al. Prevention and treatment of thrombosis in pediatric and congenital heart disease - A scientific statement from the American Heart Association. Circulation. 2013;128:2622\u2013703.","journal-title":"Circulation."},{"key":"529_CR64","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s00246-010-9715-8","volume":"31","author":"C Manlhiot","year":"2010","unstructured":"Manlhiot C, Brand\u00e3o LR, Somji Z, Chesney AL, MacDonald C, Gurofsky RC, et al. Long-term anticoagulation in Kawasaki disease: Initial use of low molecular weight heparin is a viable option for patients with severe coronary artery abnormalities. Pediatr Cardiol. 2010;31:834\u201342.","journal-title":"Pediatr Cardiol."},{"key":"529_CR65","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.jacc.2015.12.073","volume":"67","author":"JW Newburger","year":"2016","unstructured":"Newburger JW, Takahashi M, Burns JC. Kawasaki disease. J Am Coll Cardiol. 2016;67:1738\u201349.","journal-title":"J Am Coll Cardiol."},{"key":"529_CR66","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1055\/s-0038-1650540","volume":"76","author":"M Leaker","year":"1996","unstructured":"Leaker M, Massicotte MP, Brooker LA, Andrew M. Thrombolytic therapy in pediatric patients: a comprehensive review of the literature. Thromb Haemost. 1996;76:132\u20134.","journal-title":"Thromb Haemost."},{"key":"529_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.thromres.2004.12.018","volume":"118","author":"M Albisetti","year":"2006","unstructured":"Albisetti M. Thrombolytic therapy in children. Thromb Res. 2006;118:95\u2013105.","journal-title":"Thromb Res."},{"key":"529_CR68","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2141.2009.07914.x","volume":"148","author":"MD Williams","year":"2010","unstructured":"Williams MD. Thrombolysis in children. Br J Haematol. 2010;148:26\u201336.","journal-title":"Br J Haematol."},{"key":"529_CR69","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ijcard.2016.06.062","volume":"220","author":"E Bachlava","year":"2016","unstructured":"Bachlava E, Loukopoulou S, Karanasios E, Chrousos G, Michos A. Management of coronary artery aneurysms using abciximab in children with Kawasaki disease. Int J Cardiol. 2016;220:65\u20139.","journal-title":"Int J Cardiol."},{"key":"529_CR70","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.amjcard.2010.01.332","volume":"105","author":"RT McCandless","year":"2010","unstructured":"McCandless RT, Minich LL, Tani LY, Williams RV. Does abciximab promote coronary artery remodeling in patients with Kawasaki disease? Am J Cardiol. 2010;105:1625\u20138.","journal-title":"Am J Cardiol."},{"key":"529_CR71","doi-asserted-by":"publisher","DOI":"10.1542\/peds.109.1.e4","volume":"109","author":"RV Williams","year":"2002","unstructured":"Williams RV, Wilke VM, Tani LY, Minich LL. Does abciximab enhance regression of coronary aneurysms resulting from Kawasaki disease? Pediatrics. 2002;109:E4.","journal-title":"Pediatrics."},{"key":"529_CR72","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jpeds.2010.04.008","volume":"157","author":"JW Newburger","year":"2010","unstructured":"Newburger JW, Fulton DR. Coronary revascularization in patients with Kawasaki disease. J Pediatr. 2010;157:8\u201310.","journal-title":"J Pediatr."},{"key":"529_CR73","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jcin.2015.12.011","volume":"9","author":"JB Gordon","year":"2016","unstructured":"Gordon JB, Daniels LB, Kahn AM, Jimenez-Fernandez S, Vejar M, Numano F, et al. The spectrum of cardiovascular lesions requiring intervention in adults after Kawasaki disease. JACC Cardiovasc Interv. 2016;9:687\u201396.","journal-title":"JACC Cardiovasc Interv."},{"key":"529_CR74","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/BF02066356","volume":"1","author":"A Suzuki","year":"1985","unstructured":"Suzuki A, Kamiya T, Ono Y, Takahashi N, Naito Y, Kou Y. Indication of aortocoronary by-pass for coronary arterial obstruction due to Kawasaki disease. Heart Vessels. 1985;1:94\u2013100.","journal-title":"Heart Vessels."},{"key":"529_CR75","doi-asserted-by":"publisher","DOI":"10.5812\/ijp.3875","volume":"26","author":"S Kitamura","year":"2016","unstructured":"Kitamura S. Pediatric coronary artery revascularization surgery: development and effects on survival, cardiac events and graft patency for children with Kawasaki disease coronary involvements. Iran J Pediatr. 2016;26:e3875.","journal-title":"Iran J Pediatr."},{"key":"529_CR76","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4070\/kcj.2011.41.2.53","volume":"41","author":"T Akagi","year":"2011","unstructured":"Akagi T. Catheter interventions for Kawasaki disease: current concepts and future directions. Korean Circ J. 2011;41:53\u20137.","journal-title":"Korean Circ J."},{"key":"529_CR77","doi-asserted-by":"publisher","first-page":"19796","DOI":"10.3402\/ljm.v7i0.19796","volume":"7","author":"SM Yuan","year":"2012","unstructured":"Yuan SM. Cardiac surgical procedures for the coronary sequelae of Kawasaki disease. Libyan J Med. 2012;7:19796.","journal-title":"Libyan J Med."},{"key":"529_CR78","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00246-006-1276-5","volume":"27","author":"E Tsuda","year":"2006","unstructured":"Tsuda E, Miyazaki S, Yamada O, Takamuro M, Takekawa T, Echigo S. Percutaneous transluminal coronary rotational atherectomy for localized stenosis caused by Kawasaki disease. Pediatr Cardiol. 2006;27:447\u201353.","journal-title":"Pediatr Cardiol."},{"key":"529_CR79","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/ccd.10226","volume":"56","author":"TF Peters","year":"2002","unstructured":"Peters TF, Parikh SR, Pinkerton CA. Rotational ablation and stent placement for severe calcific coronary artery stenosis after Kawasaki disease. Catheter Cardiovasc Interv. 2002;56:549\u20135.","journal-title":"Catheter Cardiovasc Interv."},{"key":"529_CR80","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1756-185X.13219","volume":"21","author":"A Dionne","year":"2018","unstructured":"Dionne A, Dahdah N. Myocarditis and Kawasaki disease. Int J Rheum Dis. 2018;21:45\u20139.","journal-title":"Int J Rheum Dis"},{"key":"529_CR81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/CIRCIMAGING.112.000159","volume":"6","author":"JC Muniz","year":"2013","unstructured":"Muniz JC, Dummer K, Gauvreau K, Colan SD, Fulton DR, Newburger JW. Coronary artery dimensions in febrile children without Kawasaki disease. Circ Cardiovasc Imaging. 2013;6:239\u201344.","journal-title":"Circ Cardiovasc Imaging."},{"key":"529_CR82","doi-asserted-by":"publisher","first-page":"371","DOI":"10.7182\/pit2013252","volume":"23","author":"SM Mirhosseini","year":"2013","unstructured":"Mirhosseini SM, Asadollahi S, Fakhri M. Orthotopic heart transplant for treatment-resistant cardiomyopathy in Kawasaki syndrome: report of a successful case. Prog Transplant. 2013;23:371\u20133.","journal-title":"Prog Transplant."},{"key":"529_CR83","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1161\/01.CIR.94.9.2103","volume":"94","author":"R Dhillon","year":"1996","unstructured":"Dhillon R, Clarkson P, Donald AE, Powe AJ, Nash M, Novelli V, et al. Endothelial dysfunction late after Kawasaki disease. Circulation. 1996;94:2103\u20136.","journal-title":"Circulation."},{"key":"529_CR84","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.jpeds.2007.03.056","volume":"151","author":"BW McCrindle","year":"2007","unstructured":"McCrindle BW, McIntyre S, Kim C, Lin T, Adeli K. Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis? J Pediatr. 2007;151:244\u20138.","journal-title":"J Pediatr."},{"key":"529_CR85","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1136\/adc.2006.096628","volume":"92","author":"YF Cheung","year":"2007","unstructured":"Cheung YF, Wong SJ, Ho MH. Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki disease. Arch Dis Child. 2007;92:43\u20137.","journal-title":"Arch Dis Child."},{"key":"529_CR86","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.berh.2012.12.004","volume":"27","author":"JW Cohen","year":"2013","unstructured":"Cohen JW. Cardiovascular disease due to accelerated atherosclerosis in systemic vasculitides. Best Pract Res Clin Rheumatol. 2013;27:33\u201344.","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"529_CR87","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3345\/kjp.2014.57.11.472","volume":"57","author":"YF Cheung","year":"2014","unstructured":"Cheung YF. Vascular health late after Kawasaki disease: implications for accelerated atherosclerosis. Korean J Pediatr. 2014;57:472\u20138.","journal-title":"Korean J Pediatr."},{"key":"529_CR88","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3109\/08916934.2015.1027818","volume":"48","author":"AH Tremoulet","year":"2015","unstructured":"Tremoulet AH. The role of statins in inflammatory vasculitides. Autoimmunity. 2015;48:177\u201380.","journal-title":"Autoimmunity."},{"key":"529_CR89","first-page":"737","volume":"81","author":"American Academy of Pediatrics Committee on Sports Medicine","year":"1988","unstructured":"American Academy of Pediatrics Committee on Sports Medicine. Recommendations for partecipation in competitive sports. Pediatrics. 1988;81:737\u20139.","journal-title":"Pediatrics."},{"key":"529_CR90","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1016\/j.jacc.2005.02.009","volume":"45","author":"TP Graham","year":"2005","unstructured":"Graham TP, Driscoll DJ, Gersony WM, Newburger JW, Rocchini A, Towbin JA. 36th Bethesda Conference. Eligibility recommendations for competitive athletes with cardiovascular abnormalities. Task Force 2: Congenital Heart Disease. J Am Coll Cardiol. 2005;45:1326\u201333.","journal-title":"J Am Coll Cardiol."},{"key":"529_CR91","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1016\/j.jacc.2005.02.013","volume":"45","author":"PD Thompson","year":"2005","unstructured":"Thompson PD, Balady GJ, Chaitman BR, Clark LT, Levine BD, Myerburg RJ. 36th Bethesda Conference. Eligibility recommendations for competitive athletes with cardiovascular abnormalities. Task Force 6: Coronary Artery Disease. J Am Coll Cardiol. 2005;45:1348\u201353.","journal-title":"J Am Coll Cardiol."},{"key":"529_CR92","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/01.hjr.0000199494.46708.5a","volume":"13","author":"ESC Study Group of Sports Cardiology","year":"2006","unstructured":"ESC Study Group of Sports Cardiology. Recommendations for participation in leisure-time physical activity and competitive sports for patients with ischaemic heart disease. Eur J Cardiovasc Prev Rehabil. 2006;13:137\u201349.","journal-title":"Eur J Cardiovasc Prev Rehabil."},{"key":"529_CR93","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1161\/CIRCULATIONAHA.111.028423","volume":"124","author":"T Kanai","year":"2011","unstructured":"Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: As retrospective study. Circulation. 2011;124:2822\u20138.","journal-title":"Circulation."},{"key":"529_CR94","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.imlet.2017.02.011","volume":"184","author":"L Andreozzi","year":"2017","unstructured":"Andreozzi L, Bracci B, D'Errico F, Rigante D. A master role for neutrophils in Kawasaki syndrome. Immunol Lett. 2017;184:112\u20134.","journal-title":"Immunol Lett."},{"key":"529_CR95","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1097\/INF.0b013e318220c3cf","volume":"30","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Terai M, Hamada H, Honda T, Suenaga T, Takeuchi T, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J. 2011;30:871\u20136.","journal-title":"Pediatr Infect Dis J."},{"key":"529_CR96","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.jpeds.2012.02.048","volume":"161","author":"AH Tremoulet","year":"2012","unstructured":"Tremoulet AH, Pancoast P, Franco A, Bujold M, Shimizu C, Onouchi Y, et al. Calcineurin inhibitor treatment of IVIG-resistant Kawasaki disease. J Pediatr. 2012;161:506\u201312.","journal-title":"J Pediatr."},{"key":"529_CR97","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2177\/jsci.33.249","volume":"33","author":"Y Amazaki","year":"2010","unstructured":"Amazaki Y. The calcineurin and NFAT system and its inhibition. Jpn J Clin Immunol. 2010;33:249\u201361.","journal-title":"Jpn J Clin Immunol."},{"key":"529_CR98","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3349\/ymj.2008.49.5.714","volume":"49","author":"TJ Lee","year":"2008","unstructured":"Lee TJ, Kim KH, Chun JK, Kim DS. Low-dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J. 2008;49:714\u20138.","journal-title":"Yonsei Med J."}],"container-title":["Italian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13052-018-0529-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13052-018-0529-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T10:43:29Z","timestamp":1720521809000},"score":1,"resource":{"primary":{"URL":"https:\/\/ijponline.biomedcentral.com\/articles\/10.1186\/s13052-018-0529-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,30]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["529"],"URL":"https:\/\/doi.org\/10.1186\/s13052-018-0529-2","relation":{},"ISSN":["1824-7288"],"issn-type":[{"value":"1824-7288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,30]]},"assertion":[{"value":"4 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"103"}}